These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32268137)

  • 1. The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways.
    Woodby B; Sticozzi C; Pambianchi E; Villetti G; Civelli M; Valacchi G; Facchinetti F
    Arch Biochem Biophys; 2020 May; 685():108355. PubMed ID: 32268137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
    Gianello V; Salvi V; Parola C; Moretto N; Facchinetti F; Civelli M; Villetti G; Bosisio D; Sozzani S
    Biochem Pharmacol; 2019 May; 163():371-380. PubMed ID: 30851246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
    Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
    Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of
    Fontana E; Cenacchi V; Pivetti F; Pignatti A; Pazzi T; Bondanza L; Pazzi M
    J Labelled Comp Radiopharm; 2017 Oct; 60(12):577-585. PubMed ID: 28763109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
    Singh D; Leaker B; Boyce M; Nandeuil MA; Collarini S; Mariotti F; Santoro D; Barnes PJ
    Pulm Pharmacol Ther; 2016 Oct; 40():1-6. PubMed ID: 27373438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
    Villetti G; Carnini C; Battipaglia L; Preynat L; Bolzoni PT; Bassani F; Caruso P; Bergamaschi M; Pisano AR; Puviani V; Stellari FF; Cenacchi V; Volta R; Bertacche V; Mileo V; Bagnacani V; Moretti E; Puccini P; Catinella S; Facchinetti F; Sala A; Civelli M
    J Pharmacol Exp Ther; 2015 Mar; 352(3):568-78. PubMed ID: 25576073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
    Southworth T; Kaur M; Hodgson L; Facchinetti F; Villetti G; Civelli M; Singh D
    Cytokine; 2019 Jan; 113():68-73. PubMed ID: 29934047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
    Govoni M; Bassi M; Vezzoli S; Lucci G; Emirova A; Nandeuil MA; Petruzzelli S; Jellema GL; Afolabi EK; Colgan B; Leaker B; Kornmann O; Beeh KM; Watz H; Singh D
    Respir Res; 2020 Mar; 21(1):72. PubMed ID: 32197620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
    Singh D; Beeh KM; Colgan B; Kornmann O; Leaker B; Watz H; Lucci G; Geraci S; Emirova A; Govoni M; Nandeuil MA
    Respir Res; 2019 Aug; 20(1):180. PubMed ID: 31399091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
    Singh D; Emirova A; Francisco C; Santoro D; Govoni M; Nandeuil MA
    Respir Res; 2020 Sep; 21(1):246. PubMed ID: 32962709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001.
    Cenacchi V; Salvadori M; Riccardi B; Brogin G; Ghiglieri A; Messina M; Imre G; Puccini P
    Eur J Pharm Sci; 2018 Mar; 115():100-108. PubMed ID: 29307855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amentoflavone protects against psoriasis-like skin lesion through suppression of NF-κB-mediated inflammation and keratinocyte proliferation.
    An J; Li Z; Dong Y; Ren J; Huo J
    Mol Cell Biochem; 2016 Feb; 413(1-2):87-95. PubMed ID: 26724949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding.
    Sabogal Piñeros YS; Dekker T; Smids B; Majoor CJ; Ravanetti L; Villetti G; Civelli M; Facchinetti F; Lutter R
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00557. PubMed ID: 32447834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Lea S; Mathioudakis AG
    Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
    Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
    J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminalia Chebulanin Attenuates Psoriatic Skin Lesion via Regulation of Heme Oxygenase-1.
    An J; Li T; Dong Y; Li Z; Huo J
    Cell Physiol Biochem; 2016; 39(2):531-43. PubMed ID: 27383847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers.
    Ferrari A; Compagnoni A; Nandeuil A; Maison-Blanche P
    J Cardiovasc Pharmacol; 2016 Jul; 68(1):41-8. PubMed ID: 26945156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
    Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
    Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin.
    Weng Z; Patel AB; Vasiadi M; Therianou A; Theoharides TC
    PLoS One; 2014; 9(2):e90739. PubMed ID: 24587411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.